MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
J Cell Sci. 2011 Mar 1;124(Pt 5):789-800. doi: 10.1242/jcs.077230.
Ion cotransporters, such as the Na(+)/Cl(-) cotransporter (NCC), control renal salt re-absorption and are regulated by the WNK-signalling pathway, which is over-stimulated in patients suffering from Gordon's hypertension syndrome. Here, we study the regulation of the NKCC2 (SLC12A1) ion cotransporter that contributes towards ~25% of renal salt re-absorption and is inhibited by loop-diuretic hypertensive drugs. We demonstrate that hypotonic low-chloride conditions that activate the WNK1-SPAK and OSR1 pathway promote phosphorylation of NKCC2 isoforms (A, B and F) at five residues (Ser91, Thr95, Thr100, Thr105 and Ser130). We establish that the SPAK and OSR1 kinases activated by WNK interact with an RFQV motif on NKCC2 and directly phosphorylate Thr95, Thr100, Thr105 and, possibly, Ser91. Our data indicate that a SPAK-OSR1-independent kinase, perhaps AMP-activated protein kinase (AMPK), phosphorylates Ser130 and that phosphorylation of Thr105 and Ser130 plays the most important roles in stimulating NKCC2 activity. In contrast with NCC, whose membrane translocation is triggered by SPAK-OSR1 phosphorylation, NKCC2 appears to be constitutively at the membrane. Our findings provide new insights into how NKCC2 is regulated and suggest that inhibitors of SPAK and/or OSR1 for the treatment of hypertension would be therapeutically distinct from thiazide or loop diuretics, as they would suppress the activity of both NCC and NKCC2.
离子协同转运蛋白,如钠/氯协同转运蛋白(NCC),控制肾脏盐重吸收,并受 WNK 信号通路调节,该通路在患有 Gordon 高血压综合征的患者中过度刺激。在这里,我们研究了 NKCC2(SLC12A1)离子协同转运蛋白的调节,该蛋白对约 25%的肾脏盐重吸收有贡献,并被噻嗪类利尿剂降压药物抑制。我们证明,激活 WNK1-SPAK 和 OSR1 通路的低渗低氯条件促进 NKCC2 同工型(A、B 和 F)在五个残基(Ser91、Thr95、Thr100、Thr105 和 Ser130)上磷酸化。我们确定由 WNK 激活的 SPAK 和 OSR1 激酶与 NKCC2 上的 RFQV 基序相互作用,并直接磷酸化 Thr95、Thr100、Thr105,并且可能磷酸化 Ser91。我们的数据表明,一种 SPAK-OSR1 非依赖性激酶,也许是 AMP 激活的蛋白激酶(AMPK),磷酸化 Ser130,并且 Thr105 和 Ser130 的磷酸化在刺激 NKCC2 活性方面起着最重要的作用。与 SPAK-OSR1 磷酸化触发其膜易位的 NCC 不同,NKCC2 似乎在膜上是组成型的。我们的发现提供了 NKCC2 如何被调节的新见解,并表明 SPAK 和/或 OSR1 的抑制剂用于治疗高血压将在治疗上与噻嗪类或袢利尿剂不同,因为它们会抑制 NCC 和 NKCC2 的活性。